Treatment strategies for embryonal tumors with multilayered rosettes

Plain-English translation of NCT06861244 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing different treatment approaches for embryonal tumors with multilayered rosettes (ETMR), a rare brain tumor. Depending on your tumor's characteristics and how much surgery removed, you'll receive chemotherapy, radiation, or both — with some patients getting high-dose chemotherapy combined with stem cell rescue. The goal is to improve survival and understand which treatment approach works best for different patients.

ETMR is a rare and serious brain tumor, and doctors are still learning the best way to treat it. This trial exists to determine whether adding early radiation helps some patients, and whether high-dose chemotherapy with stem cell rescue might benefit others — so that future patients get the most effective treatment based on their individual situation.

Do you qualify?

You likely qualify if…

you have been diagnosed with embryonal tumor with multilayered rosettes (confirmed by a pathologist or genetic testing)
you have had surgery to remove the tumor before starting this trial
you have not received radiation therapy before
your blood counts and organ function (kidneys, liver) are healthy enough to tolerate chemotherapy
you are well enough to be up and active most of the time, even if you need a wheelchair

You likely don't qualify if…

you have received chemotherapy or other tumor-directed therapy before (unless you're in Cohort 2 or 3, which allows prior therapy)
you have received radiation therapy to treat your tumor
your blood cell counts or organ function are too low to safely start chemotherapy
you are unable to begin treatment within 28 days of your surgery

What participation looks like

You will be assigned to one of four treatment groups based on how much of your tumor was removed and whether it has spread. Your group will determine whether you receive standard-dose chemotherapy with early radiation (18 weeks), or high-dose chemotherapy with stem cell rescue over 18–24 weeks. You'll visit the hospital regularly for chemotherapy infusions, scans, and blood tests, and you'll be followed for up to 2 years to monitor how well the treatment is working and how you're doing.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Trial locations(8 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

University of California, San Francisco, San Francisco, California

Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana

Johns Hopkins University, Baltimore, Maryland

Washington University in St. Louis, St Louis, Missouri